Written Communication by the Subject Company Relating to a Third Party Tender Offer (sc14d9c)
September 01 2022 - 8:15AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14D-9
SOLICITATION/RECOMMENDATION STATEMENT
UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934
Forma Therapeutics Holdings, Inc.
(Name of Subject Company)
Forma
Therapeutics Holdings, Inc.
(Name of Persons Filing Statement)
COMMON STOCK, PAR VALUE $0.001 PER SHARE
(Title of Class of Securities)
34633R104
(CUSIP Number
of Class of Securities)
Frank D. Lee
Forma Therapeutics Holdings, Inc.
President & Chief Executive Officer
300 North Beacon Street
Suite 501
Watertown,
Massachusetts 02472
(617) 679-1970
With copies to:
Stuart M. Cable, Esq.
Lisa R. Haddad, Esq.
William D. Collins, Esq.
Andrew H. Goodman, Esq.
Goodwin Procter LLP
100
Northern Avenue
Boston, MA 02210
(617) 570-1000
(Name, address, and telephone numbers of person authorized to receive notices and communications
on behalf of the persons filing statement)
☒ |
|
Check the box if the filing relates solely to preliminary communications made before the commencement of a tender
offer. |
The information set forth under Items 1.01, 8.01 and 9.01 of the Current Report on Form
8-K filed by Forma Therapeutics Holdings, Inc. on September 1, 2022 (including all exhibits attached thereto) is incorporated herein by reference.
Forma Therapeutics (NASDAQ:FMTX)
Historical Stock Chart
From Jul 2024 to Aug 2024
Forma Therapeutics (NASDAQ:FMTX)
Historical Stock Chart
From Aug 2023 to Aug 2024
Real-Time news about Forma Therapeutics Holdings Inc (NASDAQ): 0 recent articles
More Forma Therapeutics Holdings, Inc. News Articles